These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9811500)

  • 61. A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery.
    Li JK; Wang N; Wu XS
    J Pharm Sci; 1997 Aug; 86(8):891-5. PubMed ID: 9269865
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A nano particle vector comprised of poly lactic-co-glycolic acid and monophosphoryl lipid A and recombinant Mycobacterium avium subsp paratuberculosis peptides stimulate a pro-immune profile in bovine macrophages.
    Souza CD; Bannantine JP; Brown WC; Norton MG; Davis WC; Hwang JK; Ziaei P; Abdellrazeq GS; Eren MV; Deringer JR; Laws E; Cardieri MCD
    J Appl Microbiol; 2017 Jul; 123(1):54-65. PubMed ID: 28502107
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
    Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
    Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines.
    Ertl HC; Varga I; Xiang ZQ; Kaiser K; Stephens L; Otvos L
    Vaccine; 1996 Jun; 14(9):879-85. PubMed ID: 8843629
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice.
    Nikou KN; Stivaktakis N; Avgoustakis K; Sotiropoulou PA; Perez SA; Baxevanis CN; Papamichail M; Leondiadis L
    Biochim Biophys Acta; 2005 Sep; 1725(2):182-9. PubMed ID: 16126344
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine.
    Sui D; Ma L; Li M; Shao W; Du H; Li K; Li Z; Li Z
    Mol Med Rep; 2016 Apr; 13(4):3675-83. PubMed ID: 26935338
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
    Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
    Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.
    Little SR; Lynn DM; Ge Q; Anderson DG; Puram SV; Chen J; Eisen HN; Langer R
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9534-9. PubMed ID: 15210954
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.
    Du JJ; Zhou SH; Cheng ZR; Xu WB; Zhang RY; Wang LS; Guo J
    Front Chem; 2022; 10():814880. PubMed ID: 35186882
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres.
    Gutierro I; Hernández RM; Igartua M; Gascón AR; Pedraz JL
    Vaccine; 2002 May; 20(17-18):2181-90. PubMed ID: 12009271
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen.
    Lofthouse SA; Apostolopoulos V; Pietersz GA; Li W; McKenzie IF
    Vaccine; 1997 Oct; 15(14):1586-93. PubMed ID: 9330472
    [TBL] [Abstract][Full Text] [Related]  

  • 72. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine.
    Wang H; Yang B; Wang Y; Liu F; Fernández-Tejada A; Dong S
    Chem Commun (Camb); 2018 Dec; 55(2):253-256. PubMed ID: 30534737
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preparation of neurotensin analogue-containing poly(dl-lactic acid) microspheres formed by oil-in-water solvent evaporation.
    Yamakawa I; Tsushima Y; Machida R; Watanabe S
    J Pharm Sci; 1992 Sep; 81(9):899-903. PubMed ID: 1432637
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 3D-Printed Drug/Cell Carrier Enabling Effective Release of Cyclosporin A for Xenogeneic Cell-Based Therapy.
    Song TH; Jang J; Choi YJ; Shim JH; Cho DW
    Cell Transplant; 2015; 24(12):2513-25. PubMed ID: 25608278
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PEGylated PLGA Nanoparticle Delivery of Eggmanone for T Cell Modulation: Applications in Rheumatic Autoimmunity.
    Haycook CP; Balsamo JA; Glass EB; Williams CH; Hong CC; Major AS; Giorgio TD
    Int J Nanomedicine; 2020; 15():1215-1228. PubMed ID: 32110018
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Potentiating the immune response of MUC1-based antitumor vaccines using a peptide-based nanovector as a promising vaccine adjuvant.
    Liu Y; Wang Y; Yu F; Zhang Z; Yang Z; Zhang W; Wang PG; Zhao W
    Chem Commun (Camb); 2017 Aug; 53(68):9486-9489. PubMed ID: 28799590
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthesis and Immunological Comparison of Differently Linked Lipoarabinomannan Oligosaccharide-Monophosphoryl Lipid A Conjugates as Antituberculosis Vaccines.
    Wang L; Feng S; Wang S; Li H; Guo Z; Gu G
    J Org Chem; 2017 Dec; 82(23):12085-12096. PubMed ID: 29112822
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Enhancing Macrophage Drug Delivery Efficiency via Co-Localization of Cells and Drug-Loaded Microcarriers in 3D Resonant Ultrasound Field.
    Lee YH; Wu ZY
    PLoS One; 2015; 10(8):e0135321. PubMed ID: 26267789
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes.
    Arabi A; Aria Soltani S; Maniaci B; Mann K; Martinson H; Kullberg M
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140114
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen.
    Pifferi C; Aguinagalde L; Ruiz-de-Angulo A; Sacristán N; Baschirotto PT; Poveda A; Jiménez-Barbero J; Anguita J; Fernández-Tejada A
    Chem Sci; 2023 Mar; 14(13):3501-3513. PubMed ID: 37006677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.